|Home | About | Journals | Submit | Contact Us | Français|
Conceived and designed the experiments: LZ DC. Performed the experiments: LZ MS LL LL DC. Analyzed the data: LZ MS WN SG DC. Contributed reagents/materials/analysis tools: LL LL WN DC. Wrote the paper: WN SG DC.
Several lines of investigation support the notion that endocytosis is crucial for Alzheimer’s disease (AD) pathogenesis. Substantial evidence have already been reported regarding the mechanisms underlying amyloid precursor protein (APP) traffic, but the regulation of beta-site APP-Cleaving Enzyme 1 (BACE-1) distribution among endosomes, TGN and plasma membrane remains unclear. Dynamin, an important adaptor protein that controls sorting of many molecules, has recently been associated with AD but its functions remain controversial. Here we studied possible roles for dynamin 1 (dyn1) in Aβ biogenesis.
We found that genetic perturbation of dyn1 reduces both secreted and intracellular Aβ levels in cell culture. There is a dramatic reduction in BACE-1 cleavage products of APP (sAPPβ and βCTF). Moreover, dyn1 knockdown (KD) leads to BACE-1 redistribution from the Golgi-TGN/endosome to the cell surface. There is an increase in the amount of surface holoAPP upon dyn1 KD, with resultant elevation of α–secretase cleavage products sAPPα and αCTF. But no changes are seen in the amount of nicastrin (NCT) or PS1 N-terminal fragment (NTF) at cell surface with dyn1 KD. Furthermore, treatment with a selective dynamin inhibitor Dynasore leads to similar reduction in βCTF and Aβ levels, comparable to changes with BACE inhibitor treatment. But combined inhibition of BACE-1 and dyn1 does not lead to further reduction in Aβ, suggesting that the Aβ-lowering effects of dynamin inhibition are mainly mediated through regulation of BACE-1 internalization. Aβ levels in dyn1−/− primary neurons, as well as in 3-month old dyn1 haploinsufficient animals with AD transgenic background are consistently reduced when compared to their wildtype counterparts.
In summary, these data suggest a previously unknown mechanism by which dyn1 affects amyloid generation through regulation of BACE-1 subcellular localization and therefore its enzymatic activities.
Late-onset Alzheimer’s disease (LOAD) typically manifests after the sixth decade, accounting for over 95% of all AD cases. Genetic studies of LOAD point to a number of risk factor genes, such as apolipoprotein E epsilon4 (ApoEε4) allele , and several endocytic proteins. For example, single nucleotide polymorphism (SNP) studies from two research groups studying Japanese and Belgian populations have independently identified an association of dynamin binding protein gene (DNMBP) on chromosome 10 to LOAD, particularly in individuals lacking the APOE ε4 allele , . Furthermore, a significant association of LOAD with the dynamin 2 (DNM2) gene was detected by SNP analysis, especially in non-carriers of the ApoEε4 allele , .
Dynamin is a GTPase that plays a critical role in endocytic vesicle fission . It is encoded by three different genes (DNM1, DNM2, and DNM3) in mammals . Dynamin 1 (dyn1) is highly and selectively expressed in the nervous system and represents the major dynamin isoform expressed in this tissue . Dyn1 has been linked to the biology of AD. For example, dominant-negative dyn1 (K44A mutant), which blocks endocytosis, reduces Aβ levels in interstitial spinal fluid (ISF) and prevents activity-dependent increases in Aβ . Dyn1 K44A mutant also reduces oligomer Aβ42-induced neuronal death  and increases APP ectodomain shedding . Others showed an increase in BACE-1 cleavage of APP and Aβ generation at the cell surface in dyn1 K44A expressing HeLa cells . Taken together, a role for dyn1 in AD is implicated but precise molecular mechanism(s) remains elusive.
Herein, we report that using gene silencing techniques to knockdown dyn1 levels reduces both secreted and intracellular Aβ levels in cell culture. There is a dramatic reduction in beta-site APP-Cleaving Enzyme 1 (BACE-1) cleavage products of APP (sAPPβ and βCTF). Moreover, dyn1 knockdown (KD) leads to BACE-1 redistribution from the Golgi-TGN/endosome to the cell surface. There is an increase in the amount of surface holoAPP upon dyn1 KD, with resultant elevation of α–secretase cleavage products sAPPα and αCTF. But no changes are seen in the amount of nicastrin (NCT) or PS1 N-terminal fragment (NTF) at cell surface with dyn1 KD. Furthermore, treatment with a selective dynamin inhibitor Dynasore leads to similar reduction in βCTF and Aβ levels, comparable to changes with BACE inhibitor treatment. But combined inhibition of BACE-1 and dyn1 does not lead to further reduction in Aβ, suggesting that the Aβ-lowering effects of dynamin inhibition are mainly mediated through regulation of BACE internalization. Aβ Levels in dyn1−/− primary neurons, as well as in 3-month old dyn1 haploinsufficient animals with AD transgenic background are consistently reduced when compared to their wildtype counterparts.
In summary, these data suggest a previously unknown modulatory mechanism by which dyn1 affects amyloid generation through regulation of BACE-1 subcellular localization and therefore its enzymatic activities. Together, our findings provide mechanistic evidence that inhibition of dyn1 functions may prevent certain pathologic changes associated with AD.
All animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal studies were approved by the Institutional Animal Care and Use Committee of James J Peters VA Medical Center (Permit Number: CAI-10-044a). All efforts were made to minimize suffering.
4G8, 6E10 and sAPPβ (Covance), anti-APP N-terminus MAB348 (clone 22C11, Millipore) and anti-BACE C-terminus MAB5308 (clone 61, Millipore), anti-dynamin clone 41, anti-EEA1, anti-γ-adaptin and anti-nicastrin (NCT) (BD Transduction), anti-β actin (Santa Cruz), anti-Pen-2 antibody NE1008 (Calbiochem), anti-mouse and rabbit HRP conjugates (Vector Laboratories), Texas- Red conjugated anti-mouse IgG (Vector Laboratories Inc.) were purchased. pAb369 (C-terminal APP antibody) , RU690 (C-terminal BACE1 antibody) , RUWN-b1 (C-terminal sAPPβ antibody), RU717 (N-terminal nicastrin antibody)  and Ab14 (N-terminal PS1 antibody)  generously provided by Dr. Greengard at The Rockefeller University, were also used for APP/CTFs, BACE1, sAPPβ, NCT and PS1 detection. Synthetic sAPPβ peptide (Covance) and BACE-1 lysates from 293 cells (Santa Cruz Biotechnology) were used as positive controls.
N2a cells stably transfected with cDNAs encoding human APP695 provided by Dr. Greengard at The Rockefeller University  were transfected with dyn1siRNA and maintained for 4–5 days to achieve about 50–80% knockdown of dyn1 protein levels. Fibroblast cell lines from dynamin 1, dynamin 2 conditional knockout mice expressing tamoxifen-inducible Cre recombinase (dyn KD) provided by Dr. Pietro De Camilli at Yale School of Medicine  lose dynamin expression upon treatment with 1µM 4-hydroxy-tamoxifen. Wild type fibroblast cells were treated by tamoxifen as a control. Alternatively, cells were treated with a dyn inhibitor Dynasore  at 10 µM (Sigma), or a BACE inhibitor at 15 µM (Inhibitor IV, EMD) overnight before subjected for further analysis.
Postnatal day 0–1 cortical neurons from dyn1+/+ or dyn1−/− mouse pups  were cultured on poly-D-lysine (Sigma) pre-coated dishes for 14–21 days.
The siRNA duplexes specifically targeting dyn1 (IDT Inc.) were synthesized. Sequences are as follows: forward 5′-rGrGrC rUrUrA rCrArU rGrArA rUrArC rCrArA rCrCrA rCrGA A-3′; reverse, 5′-rUrUrC rGrUrG rGrUrU rGrGrU rArUrU rCrArU rGrUrA rArGrCrCrArG-3′. Stealth siRNA Control GC Duplex was used as a negative control (IDT Inc.). Sequences are as follows: forward 5′-rCrGrU rUrArA rUrCrG rCrGrU rArUrA rCrGrC rGrUA T-3′; reverse, 5′-rArUrA rCrGrC rGrUrA rUrUrA rUrArC rGrCrG rArArC rGrArC-3′.
For siRNA analysis, N2a 695 cells were seeded at 50% to 60% confluence and transfected with 200 pmol siRNA dyn1 versus control duplex using Lipofectamine RNAimax (Invitrogen). For transient transfection of cDNA constructs, dyn KD fibroblasts were seeded at 70% confluence and transfected with 0.5 µg of BACE1-EGFP cDNA provided by Dr. Bradley Hyman at Harvard Medical Center,  using Lipofectamine 2000 (Invitrogen).
After transfection, cells were harvested in lysis buffer . Equal amounts of total protein were loaded for Western blot using 6E10 to detect holoAPP (full-length APP). Aβ40 and Aβ42 levels in media were determined by human ELISA kits (WAKO), according to the manufacturer’s instructions. Alternatively, mouse Aβ40 levels in media of Dyn KD fibroblasts after various treatments were determined by mouse ELISA kits (WAKO).
Media or lysates were diluted with immunoprecipitation buffer  and immunoprecipitated using 4G8 followed by immunoblotted with 6E10 for Aβ and βCTF detection. Media were immunoprecipitated using MAB348 (Millipore) followed by immunoblotted with sAPPβ antibody (for sAPPβ) or 6E10 antibody (for sAPPα).
Dyn KD fibroblasts were incubated at 4°C with 0.5 mg/ml sulfo N-hydroxysuccinimide biotin (Pierce) to label surface proteins as described previously . Samples of both biotinylated and non-biotinylated BACE-1 were analyzed by Western blot using MAB5308 or RU690. Purified lysates from BACE-1 expressing 293 cells were used as positive controls. Alternatively, samples of both biotinylated and non-biotinylated holoAPP were analyzed by Western blot using 6E10.
Dyn KD fibroblasts transfected with EGFP-BACE1 were treated with or without tamoxifen for dyn1 knockdown, followed by fixation and permeabilization. Cells were then incubated with primary antibody against an endosomal marker EEA1 (11000) or a Golgi/TGN marker γ-adaptin (11000) following incubation with Texas Red conjugated anti-mouse IgG (11000). Immunofluorescence staining was examined by confocal microscopy (LSM510, Zeiss).
Primary neurons derived from dyn1+/+ or dyn1−/− animals  were labeled with [35S] methionine (500 µCi/ml) for 5 hours at 37°C. Media was immunoprecipitated with 4G8 and then subjected to autoradiography to determine levels of Aβ1–40/42 and Aβ11–40/42 , .
Human Swedish βAPP and FAD-linked PS1 ΔE9 mutant transgenic mice from Jackson Laboratory ,  were mated with heterozygous dyn1 null mice (dyn1+/−) provided by Dr. Pietro De Camilli from Yale School of Medicine . Double heterozygous F1s were then bred with heterozygous dyn1 null mice only to generate offsprings that express human Swedish APP and FAD-linked PS1 ΔE9 in the dyn1+/+ or dyn1+/− background. Genotypes were determined by PCR amplification as described previously.
Mouse brains from APP/PS1+/− dyn1+/+ or APP/PS1+/− dyn1+/− at 2–3 months of age, were rapidly dissected and snap frozen for further analysis. Each frozen hemi-brain was then processed via step-wise solubilization , . Lysates were analyzed by Western blot using 6E10 to determine levels of holoAPP and βCTF. Levels of Aβ40 were determined by human Aβ40 ELISA kits (WAKO), according to the manufacturer’s instructions. Results were normalized to wet brain weight and expressed as picomoles per gram.
Densitometric analysis of western blot bands (integrated density) was performed using Multigauge v3.1 software (Fujifilm). Levels of holoAPP, βCTF, sAPPβ/α, Aβ and BACE-1 were normalized to actin and expressed as percentage of control. Absolute Aβ40 concentrations were quantitatively determined by sandwich ELISA (Wako). Independent-samples t tests (parametric design) were used to determine significant mean differences between groups. Significance for t tests are reported with a p<0.05 using two-tailed tests with an α level of 0.05. All statistical analysis was performed using SPSS v18.0.
To determine whether dyn1 modulates APP metabolism, we first analyzed the effects of dyn1 knockdown on levels of APP and its metabolites in N2a cells stably expressing human APP695 (N2a 695 cells). Using siRNA transfection methods, 50–80% reduction in dyn1 protein levels was achieved after 4–5 days. Both secreted and intracellular Aβ levels were significantly decreased by 64.5% and 77.8% respectively, compared to control siRNA transfection (Fig.1A, p<0.001). There was 62.5% reduction in Aβ40 and 44.7% reduction in Aβ42 levels measured by sandwich ELISA (Fig.1B, p<0.001). There was a dramatic reduction in other APP metabolites sAPPβ and βCTF levels (57.4%, p=0.021 and 45.7%, p<0.001 respectively), without significant changes in holoAPP levels (119.16% of controls, p=0.101). In addition, the levels of BACE-1 as well as γ-secretase components such as PS1 NTF and Pen-2 were unchanged (Figure S1A).
To confirm the specificity of effects of dyn1 siRNA on APP metabolism, three different dynamin 1 siRNA duplex constructs were synthesized (IDT Inc.) and transfected into N2a 695 cells to determine APP processing. Secreted Aβ levels were similarly decreased by all three siRNA constructs compared to control siRNA transfection (Figure S1B). The specificity of Aβ detection was determined by comparing to transfection of APP siRNA. Moreover, to confirm the specificity of βCTF detection, lysates from N2a 695 cells with dyn1 or control siRNA transfection were immunoprecipitated with 4G8 followed by immunoblotting with 6E10 (Figure S1B, left panels) to determine levels of βCTF and Aβ. Alternatively, lysates were directly blotted with 6E10 to detect holoAPP, βCTF and Aβ, followed by reprobing with 369 for detection of α/βCTF (Figure S1C, right panels).
Based on our findings, the consistent changes in levels of βCTF and sAPPβ support the notion that dyn1 knockdown inhibits APP cleavage by BACE-1 rather than accelerating degradation of βCTF.
Next, we evaluated the effects of dyn1 knockdown on BACE1 intracellular traffic using dyn1 knockdown (KD) fibroblasts derived from dyn conditional knockout mice expressing tamoxifen-inducible Cre recombinase . These experimental conditions allowed us to study dynamic changes in BACE-1 with inducible dyn1 down-regulation. After tamoxifen treatment at 1µM for 5–7 days, dyn1 protein levels were reduced by 56.6% (Figure S2A, p=0.03) in the KD fibroblasts. Alternatively, wildtype fibroblast cells were treated with tamoxifen as a control and there was no change in dyn1 protein levels with tamoxifen treatment (Figure S2B, right panel). Similar to the results using dyn1 siRNA in the N2a 695 cell line, reduced βCTF levels (Figure S2A; 66.7% of reduction, p=0.008) were observed in dyn1 KD fibroblasts with tamoxifen treatment. Tamoxifen treatment in wildtype cells did not cause any changes in α/βCTF levels, ruling out an effect of tamoxifen itself (Figure S2B, left panel).
BACE-1 intracellular distribution in dyn1 KD cells was studied after transfection with EGFP-BACE1 construct . As shown in Fig. 2, amounts of EGFP-BACE-1 at the cell surface were significantly increased with dyn1 knockdown. Under control conditions, BACE-1 (green fluorescence) was mainly localized in the endosomes and TGN/Golgi, determined by an endosomal marker EEA1 (red fluorescence, Fig. 2A,) as well as a TGN marker γ-adaptin (red fluorescence, Figure 2B). However, after dyn1 knockdown, amounts of green fluorescence (EGFP-BACE1) were dramatically increased at cell surface with little remaining within the TGN/Golgi and endosomes. Transfected EGFP-BACE-1 expression levels were comparable between control cells and dyn1 KD cells (Figure S3A).
Using surface biotinylation methods, we next analyzed the intracellular and surface distribution of endogenous BACE-1 in dyn1 KD fibroblasts without over-expression of EGFP-BACE-1. As shown in Fig.3A (top panel), surface BACE-1 levels were elevated by 251.8% with dyn1 knockdown when compared to controls (p=0.047). There was a modest elevation in total BACE-1 protein levels without achieving statistical significance (increase by 78.5%, p=0.08). The specificity of BACE-1 detection was confirmed by using cell lysates extracted from BACE-1 expressing 293 cells as positive controls.
Interestingly, cell surface holoAPP levels in dyn KD cells were also elevated by 131.1% (p=0.02) upon tamoxifen induction, without any significant changes in total APP protein levels (111.6% of controls, p=0.615) as shown in Figure 3B. In addition, the levels of sAPPα in N2a 695 cells determined by immunoprecipitation with MAB348 followed by immunoblotting with 6E10 antibody, was increased by 286.3% (p=0.042) upon dyn1 knockdown by siRNA transfection. Consistently, the levels of αCTF were also elevated with dyn1 KD in both N2a 695 cells (Figure S1C) and in dyn1 KD fibroblasts (Figure S2A; increase by 84.9%, p=0.011). The increased holoAPP at cell surface likely promotes α-secretase cleavage to generate sAPPα and αCTF.
However, it should be noted that dyn1 knockdown does not have a general effect on internalization of all proteins because no significant changes were seen in the amounts of nicastrin (NCT) or PS1 NTF at cell surface upon dyn KD conditions (Figure S3B). In addition, the total protein levels of NCT and NCT were unchanged with dyn1 KD (Figure S3B, input panels). The changes in both BACE-1 and holoAPP at cell surface with dyn1 KD suggest that dyn1 regulates a common trafficking pathway for those two proteins between endosomes and plasma membrane.
Taken together, these data suggest that dyn1 knockdown inhibits endocytosis of BACE-1, thereby preventing delivery of BACE-1 to its active sites in endosomes . The BACE-1 on the cell surface is likely to be inactive and unable to process holoAPP to generate βCTF and Aβ. Therefore, increased holoAPP availability at surface for α-secretase cleavage leads to elevation in sAPPα (Figure 3B) and αCTF (Figure S1C and S2A).
Next, to determine whether pharmacological inhibition of dyn1 could affect APP processing, N2a 695 cells were treated with a selective dynamin inhibitor dynasore at 10µM , , . As shown in Figure 4A, levels of βCTF and Aβ secreted in media were decreased by 47.4% (p=0.008) and 70.4% (p<0.001), comparable to that with a BACE inhibitor treatment  (reduction of βCTF by 38% p=0.006, and Aβ by 50.4% p=0.011).
Furthermore, the effects of dyn1 knockdown on BACE-1 cleavage of endogenous APP were confirmed in dyn1 KD fibroblast cell lines. Similar to the results using siRNA and chemical inhibitors in N2a 695 cells, reduction in βCTF levels (Figure S2A; 66.7% of reduction, p=0.008) was observed in these cells upon dyn1 knockdown. The total Aβ40 levels measured by sandwich ELISA were reduced by 39.4% (p<0.001), comparable to the reduction induced by a BACE inhibitor treatment (41.3% reduction, p<0.001; Fig. 4B). However, the combination of BACE inhibitor IV with tamoxifen-induced dyn1 KD did not lead to further reduction in Aβ40 levels than either treatment alone (41.3% reduction). Consistently, Aβ40 levels were reduced by 40% in dyn1 KD fibroblasts with dynasore treatment alone. The combination of dynasore and BACE inhibitor treatment did not lead to further reduction in Aβ40 levels as well (43.5% reduction). The lack of additive effects with combined treatments suggests that the Aβ-lowering effects of dyn1 KD, dynasore and BACE inhibitor IV all act through the same step: BACE1 inhibition.
Dyn1 has been implicated in regulating activity-dependent Aβ secretion through endocytosis . To determine whether dyn1 has a direct effect on endogenous Aβ generation, we next analyzed levels of newly synthesized Aβ secreted from dyn1−/− neurons  using S35-methionine labeling approach. When compared to dyn1+/+ neurons, levels of S35-labeled Aβ (both Aβ1–40/42 and Aβ11–40/42 species as described previously , ) secreted into the media were decreased by 55.9% in dyn1−/− neurons after 5 hours of incubation (Fig. 5A, p=0.004). The dyn1 genotypes were confirmed by PCR results (Fig. 5A, middle panel) and the levels of β-actin were comparable between dyn1+/+ and dyn1−/− neurons (Fig.5A, bottom panel).
Dyn1 knockout animals can only survive up to 2 weeks . To determine whether genetic perturbation of dyn1 affects Aβ generation in adult animals in vivo, we next analyzed the levels of Aβ, holoAPP and βCTF in the brains of dyn1 haploinsufficient (dyn1+/−) mice with AD transgenic background expressing human Swedish APP and PS1ΔE9 mutations , . At 2–3 months of age, levels of Aβ40 determined by sandwich ELISA in total brain lysates from AD transgenic mice carrying dyn1 haploinsufficiency (n=8), were decreased by 35.5% when compared to controls (n=9; p=0.013; Fig. 5B). However, levels of Aβ42 at this age group were too low for detection of any statistically significant changes. The levels of βCTF in the brains of dyn1 haploinsufficient animals (dyn1+/−) were slightly decreased (13.7%) when compared to dyn1 wild-type (dyn1+/+) animals (Figure S4). There was a trend of reduction in βCTF in dyn1+/− mouse brains, but due to large variations in these transgenic animals (even within the same group), this effect did not achieve statistical significance (p=0.613). The levels of holoAPP were comparable between the two groups (Figure S4107.4% of controls in dyn1+/− mice; p=0.679).
It is well established that sorting mechanisms which cause APP, BACE-1 and γ-secretase to colocalize in the same subcellular compartment play important roles in the regulation of Aβ production . Further, endocytic pathways are important for regulation of BACE-1 activity (Huse et al., 2000). Substantial data regarding the nature and mechanisms underlying APP endocytosis have been reported, but the role of endocytosis in regulating BACE-1 distribution among endosomes, TGN and plasma membrane remain unclear.
As an important endocytic adaptor protein, the involvement of dynamin in Aβ biogenesis has been described , , , raising the possibility that it may affect Aβ biogenesis as a step in the pathogenesis of AD. However, there are discrepancies between prior reports regarding its effects on Aβ. One group showed increased cell surface Aβ production with dominant negative dyn1 K44A  but other groups reported reduced Aβ production by dyn1 K44A , . It was also suggested that impaired APP endocytosis by dyn1 K44A contributes to reduction in activity-dependent Aβ secretion . A similar situation has been proposed for deficiencies of other sorting proteins (e.g., SorL1 and Vps35), both of which, like dynamin, will undoubtedly alter sorting of multiple substrates. Yet, deficiencies of either SorL1 or Vps35 can promote Aβ generation and accumulation as prominent phenotypes at the whole brain level , .
Our data, using gene silencing in three different cell lines (including N2a cells overexpressing human APP695 cells, fibroblasts with endogenous APP expression, and primary neurons derived from dyn1−/− animals), as well as in animal models, demonstrates a previously unknown mechanism by which dyn1 regulates Aβ generation; i.e., through modulation of BACE-1 traffic between the plasma membrane and endosomes. By reducing BACE-1 localization to the endosomal compartment, dyn1 inhibits Aβ generation and secretion. These data further support the idea that endosomes are the most optimal compartments for BACE-1 enzymatic activities and that prevention of BACE-1 distribution into endosomes can reduce APP processing into Aβ. The reduction of both Aβ and βCTF/sAPPβ through dyn1 knockdown may be a better therapeutic strategy compared to those targeting γ-secretase, given that recent data suggest β- but not γ-secretase-mediated proteolysis of APP causes synaptic and memory deficits in AD .
We would suggest that the previously reported effects of dyn1 knockdown on Aβ generation , ,  are more likely to be attributable to modulation of BACE-1 sorting and less likely to be attributable to the conventional wisdom that dyn1 is primarily acting via reduction of APP internalization. A combination of dynasore (or dyn1 knockdown) and BACE inhibitor treatment did not cause any further reduction in levels of Aβ generation when compared with the maximal effect of either treatment on its own (Figure 4B), consistent with the interpretation that they both act on the same pathway. If dynamin knockdown/blockade caused an inhibition of Aβ generation by acting via inhibition of APP internalization, then there would be further reduction of Aβ when the BACE inhibitor was added. Together, our data suggest that the Aβ-lowering effects of dynamin inhibition are mainly mediated through regulation of BACE-1 internalization.
Interestingly, a recent report demonstrated that an immediate early gene, Arc/Arg3.1 which recruits dynamin and endophilin to early/recycling endosomes at post-synaptic terminals, can mediate PS1/γ-secretase trafficking through the endosomal pathway, and thereby affect activity-dependent Aβ generation . These data suggest that dyn1-regulated endocytosis may also regulate γ-secretase function. However, our data demonstrate that dyn1 knockdown affects only BACE-1 and holoAPP traffic to plasma membrane but not the γ-secretase components nicastrin and PS1 NTF (Figure S3B), suggesting a shared pathway for BACE-1/holoAPP selectively regulated by dyn1.
In summary, here we report a previously unknown regulatory mechanism by which dyn1 modulates APP proteolysis and Aβ homeostasis through regulation of BACE-1 subcellular distribution. Without directly targeting BACE-1 enzymatic activities, modulation of BACE-1 subcellular localization by targeting dyn1 suggests new directions for developing therapeutic strategies for AD.
Genetic silencing of dyn1 in N2a cells reduces βCTF and Aβ levels. A) Western blot analysis of PS1 NTF by Ab14, Pen-2 by rabbit polyclonal anti Pen-2 antibody NE1008 (Calbiochem), and BACE-1 by clone 61 and RU690, were performed in N2a695 cells with transfection of dyn1 siRNA or control duplex. There were no significant differences in total protein levels of BACE-1 or γ-secretase components with dyn1 KD conditions. B) Three different dyn1 siRNA duplex were synthesized (IDT Inc.) and transfected into N2a 695 cells to determine the specificity of observed effects of dyn1 KD on APP processing. The secreted Aβ levels were similarly decreased in three different dyn1 siRNA treatment, compared to control siRNA transfection. The specificity of Aβ detection was determined by comparing to transfection of APP siRNA. Sequences of the dyn1siRNAs are as follows: Duplex 1 forward 5′-rGrGrC rUrUrA rCrArU rGrArA rUrArC rCrArA rCrCrA rCrGA A-3′; reverse, 5′-rUrUrC rGrUrG rGrUrU rGrGrU rArUrU rCrArU rGrUrA rArGrCrCrArG-3′. Duplex 2 forward 5′-rGrGrA rCrArU rArGrA rCrGrG rCrArA rGrArCrATC-3′; reverse, 5′-rGrArU rGrUrC rCrUrU rCrUrU rGrCrC rGrUrC rUrArU rGrUrC rCrUrU-3′. Duplex 3 forward 5′-rCrGrG rUrUrA rGrArC rArGrU rGrCrA rCrCrA rArGrA rArGrC T-3′; reverse, 5′-rArGrC rUrUrC rUrUrG rGrUrG rCrArC rUrGrU rCrUrA rArCrC rGrUrG-3′. Stealth siRNA Control Medium GC Duplex was used as a negative control (IDT Inc.). Sequences are described as before. APP siRNA sequences are as follows: forward 5′-rUrCrC rUrCrC rGrUrC rUrUrG rArUrA rUrUrU rGrUrC rArArC rCrCrA-3′, reverse 5′-rGrGrU rUrGrA rCrArA rArUrA rUrCrA rArGrA rCrGrg rArGGA-3′. C) Media and lysates from N2a 695 cells with dyn1 or control siRNA transfection were immunoprecipitated with 4G8 followed by immunoblotted with 6E10 to determine levels of βCTF and Aβ. Alternatively, lysates were directly blotted with 6E10 to detect holoAPP, βCTF and Aβ, followed by reprobed with 369 for detection of α/βCTF.
Dyn1 knockdown in fibroblast cells changes endogenous APP processing. A) Dyn1 KD cells were treated with tamoxifen to induce dyn1 knockdown. After tamoxifen treatment at 1 µM for 5–7 days, dyn1 protein levels were reduced by 56.6% (p=0.03) in the dyn1 KD cells. Similar to the results in N2a 695 cells, changes in metabolism of endogenous APP including reduction in βCTF levels (66.7% of reduction; p=0.008) were observed in these cells upon dyn1 knockdown. Elevation of αCTF levels was also observed (84.9% of increase; p=0.011). B) Wild type fibroblast cells were treated with tamoxifen at 1 µM for 5–7 days as a control. The levels of βCTF and αCTF, as well as dyn1 protein levels were unchanged with or without tamoxifen treatment (ctrl versus Tamoxifen).
Dyn1 knockdown increases cell surface BACE-1 levels. A) Dyn KD fibroblast cells were treated with tamoxifen to induce dyn1 knockdown followed by transiently transfected with EGFP-BACE-1. The levels of EGFP-BACE1 in dyn DKO cells with or without tamoxifen induction (three independent transfection experiments in both control and DKO cells) were comparable as shown in top panel (determined by Invitrogen anti-GFP antibody 3E6). The levels of dyn1 and actin were also determined (bottom panels). B) The amounts of nicastrin (NCT) or PS1 NTF at cell surface were also determined by biotinylation followed by streptavidin pull down. Western blot analysis of surface and total (input) NCT by anti-nicastrin antibody (BD Transduction) and RU717, as well as surface and total (input) PS1 NTF by Ab14 was performed. No significant changes were seen in the amounts of NCT and PS1NTF at cell surface or total cell lysates upon dyn KD conditions.
Genetic perturbation of dyn1 in animals slightly reduces βCTF levels. Levels of βCTF and holoAPP in total hemi-brain lysates of 3-month old APP/PS1+/− dyn1+/+ (n=9) and APP/PS1+/− dyn1+/− (n=8) mice were determined by western blot with antibody 6E10. Levels of βCTF and holoAPP were normalized to actin and presented as ratio to wild type counterparts. The levels of βCTF in the brains of dyn1 haploinsufficient animals were slightly decreased (13.7%) when compared to dyn1 wild-type animals. But due to large variations in these transgenic animals, this effect did not achieve statistical significance (p=0.613). The levels of holoAPP were comparable between two groups (107.4% of controls in dyn1+/− mice; p=0.679).
We thank Dr. Pietro De Camilli at Yale School of Medicine for scientific suggestions to this work. Fibroblast cell lines from dynamin 1, dynamin 2 conditional knockout mice as well as heterozygous dyn1 null mice (dyn1+/−) were also kindly provided by Dr. Pietro De Camilli. EGFP-BACE1 cDNA construct was kindly provided by Dr. Bradley Hyman at Harvard Medical Center. Antibodies 369, RU690, RUWN-b1, RU717 and Ab14 were kindly provided by Dr. Paul Greengard at The Rockefeller University. We also thank Drs. Gregory Elder, Noam Harel, Fred Gorelick, Michelle Ehrlich, Rachel Lane and John Steele for their critical reading of manuscript.
The authors' studies are supported by Department of Veteran Affairs Career Development Award (to D.C.) and Mount Sinai School of Medicine Friedman Brain Institute Seeding Fund (to D.C.). The funders provide financial support to our studies. They had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.